As­traZeneca de­tails ex­pan­sive com­bo strat­e­gy for new oral GLP-1 as ex­ecs wa­ger obe­si­ty mar­ket is ‘here to stay’

By ac­quir­ing Ec­co­gene’s GLP-1, As­traZeneca is bet­ting not just on the long-term po­ten­tial of the obe­si­ty drug mar­ket, but the val­ue of com­bin­ing the weight-loss drugs with pow­er­ful oth­er ther­a­pies like Farx­i­ga.

CEO Pas­cal So­ri­ot said Thurs­day that the com­pa­ny in­tends to pair ECC5004 with treat­ments in his com­pa­ny’s car­dio pipeline, strate­giz­ing a broad ap­proach to the mar­ket’s fu­ture by at­tack­ing co­mor­bidi­ties as­so­ci­at­ed with obe­si­ty.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER